Business
Rakovina Therapeutics continues to make progress as company provides corporate update
(NewsDirect) Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics continues to make progress as company provides corporate update\n \n \n (NewsDirect)\n \n \n \n \n Rakovina Therapeutics Executive Chairman\nJeffery Bacha joined Steve Darling from Proactive to discuss the\ncompany's corporate highlights as part of its second-quarter\nfinancial report.\n \n \n Bacha highlighted\nseveral significant developments for the company during this period:\nincluding a publication in the Journal of Clinical Oncology.\n \n \n Rakovina Therapeutics published a paper in\nthe Journal of Clinical Oncology describing pre-clinical data for its\nlead pre-clinical candidate, kt-3283. This data demonstrates the\npotential of kt-3283 to treat cancers that are resistant to\nfirst-generation PARP inhibitors.\n \n \n This development is crucial as it suggests that Rakovina's\ncompound could address unmet medical needs in the treatment of various\ntreatment-resistant cancers, including Ewing sarcoma.\n \n \n Bacha also said the company presented at\nthe American Association of Cancer Research. The company presented new\npreclinical in vitro and in vivo data at the annual meeting of the\nAmerican Association of Cancer Research. This data demonstrated the\npotential of Rakovina's kt-3000 series in treating\ntreatment-resistant Ewing sarcoma, a rare childhood tumor.\n \n \n The kt-3000 series is a novel class of\nDNA-damage response inhibitors designed to selectively inhibit two\nimportant anti-cancer targets: poly(ADP) ribose polymerase (PARP) and\nhistone deacetylase (HDAC).\n \n \n These developments reflect Rakovina\nTherapeutics' commitment to advancing innovative treatments for\nchallenging and resistant cancers. The company's research and\nprogress in the field of cancer therapy offer hope for patients and\nrepresent significant strides in addressing unmet medical needs.\n \n \n \n Contact Details\n \n \n \n Proactive Investors\n \n \n +1\n604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":2525,"tagName":"div"}]